Heidelberg Pharma Expands Management Team
|
DGAP-News: Heidelberg Pharma AG
/ Key word(s): Personnel
PRESS RELEASE Heidelberg Pharma Expands Management Team - Dr. András Strassz promoted to Chief Medical Officer Ladenburg, Germany, 1 March 2021 - Heidelberg Pharma AG (FSE: HPHA) today announced the appointment of Dr. András Strassz as Chief Medical Officer and Dr. Mathias Locher as Chief Development Officer. Dr. Strassz joined the company in April 2020 as Senior Medical Officer to build up the clinical development function. He has strong experience in clinical development, including in oncology. Dr. Strassz joined Heidelberg Pharma from Affimed, where he served as Medical Director. Previously, he held positions in clinical development at Sandoz and Amgen, among others. He holds both an MD and MBA from the University of Pécs, Hungary. Dr. Locher has over 30 years of experience in drug development. He joins Heidelberg Pharma from Janssen (Pharmaceutical Companies of Johnson & Johnson), where he was Senior Director - External Innovation at the J&J London Innovation Centre. Prior to that, he held management positions at Covagen, Merck Serono, Micromet (now part of Amgen) and ASTA Medica. Dr. Locher holds a PhD in biochemistry from the University of Tuebingen. Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "I am very pleased that András Strassz and Mathias Locher are joining the Heidelberg Pharma management team. With our lead program, HDP-101, about to enter the clinic, we are evolving from a research organization to a clinical development company and with strengthening the team, we gain valuable know-how and necessary expertise. I look forward to working together with the growing team to achieve our goals." About Heidelberg Pharma Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets upamostat (formerly MESUPRON(R)) and TLX250-CDx (formerly REDECTANE(R)). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at www.heidelberg-pharma.com.
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
01.03.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Gregor-Mendel-Str. 22 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1171818 |
| End of News | DGAP News Service |
Editor Details
-
Company:
- EQS Newsfeed
- Website:
